<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336450</url>
  </required_header>
  <id_info>
    <org_study_id>SHP615-302</org_study_id>
    <nct_id>NCT03336450</nct_id>
  </id_info>
  <brief_title>Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting</brief_title>
  <official_title>A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is
      safe and effective in children with status epilepticus (SE) (convulsive) in the community
      setting. This study is open-label extension for patients who completed the SHP615-301 study
      and who tolerated and responded to MHOS/SHP615 treatment in the hospital setting.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2017</start_date>
  <completion_date type="Anticipated">November 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Therapeutic Success</measure>
    <time_frame>From start of study drug administration up to 30 minutes (min) post-dose</time_frame>
    <description>Therapeutic success will be defined as the cessation of visible seizure activity within 10 minutes, with a sustained absence of visible seizure activity for 30 minutes following a single dose of MHOS/SHP615.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Seizure Event(s) Stopped Within 10 Minutes After Administration of MHOS/SHP615 and Who Have Sustained Absence of Seizure Activity for At least 1 Hour</measure>
    <time_frame>From start of study drug administration up to 1 hour (h) post-dose</time_frame>
    <description>Percentage of participants whose seizure event stopped within 10 mins of single dose administration of SHP615 and who have sustained absence of seizure activity for at least 1 h will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Seizure Event(s) Stopped Within 10 Minutes After Administration of MHOS/SHP615 and who Have Sustained Absence of Seizure Activity for At least 4 Hours</measure>
    <time_frame>From start of study drug administration up to 4 h post-dose</time_frame>
    <description>Percentage of participants whose seizure event stopped within 10 mins of single dose administration of SHP615 and who have sustained absence of seizure activity for at least 4 h will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Seizure Event(s) Stopped Within 10 Minutes After Administration of MHOS/SHP615 and Who Have Sustained Absence of Seizure Activity for At least 6 Hours</measure>
    <time_frame>From start of study drug administration up to 6 h post-dose</time_frame>
    <description>Percentage of participants whose seizure event stopped within 10 mins of single dose administration of SHP615 and who have sustained absence of seizure activity for at least 6 h will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Seizures (Convulsions)</measure>
    <time_frame>From start of study drug administration until resolution of seizure</time_frame>
    <description>Time taken for the resolution of seizures after the administration of MHOS/SHP615 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recovery of Consciousness/Baseline Mental Status</measure>
    <time_frame>From start of study drug administration until recovery of consciousness</time_frame>
    <description>Time taken for the recovery of consciousness after the administration of MHOS/SHP615 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Require Additional Anticonvulsant Medication for Ongoing SE 10 Minutes After Administration of MHOS/SHP615</measure>
    <time_frame>10 min post-dose</time_frame>
    <description>Percentage of participants who require additional anticonvulsant medication for ongoing SE according to the participating hospital protocol or guideline, 10 minutes after the administration of MHOS/SHP615 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Fail to Respond to Treatment</measure>
    <time_frame>10 min post-dose</time_frame>
    <description>Treatment failure/Nonresponder is defined as continuing seizure activity and/or the need for any additional rescue medication according to the participating healthcare setting protocol or guideline 10 minutes after administration of MHOS/SHP615</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Depression</measure>
    <time_frame>30 min, 1, 4, 6 and 24 h post-dose</time_frame>
    <description>Persistent decrease in oxygen saturation to &lt;92% measured at 1, 4, 6, and 24 hours post dose (ie, &lt;92% on room air for 2 minutes or more after dosing while monitoring [per healthcare setting protocol and/or the clinical judgment of the physician).
Increase in respiratory effort such that assisted ventilation is used (bag-valve-mask ventilation or endotracheal intubation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspiration Pneumonia</measure>
    <time_frame>From start of study drug administration up to 24 h post-dose</time_frame>
    <description>Diagnosis of aspiration pneumonia after single dose administration of SHP615.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation or Agitation as Measured by the Riker Sedation-Agitation Scale</measure>
    <time_frame>30 min, 1, 4, 6 and 24 h post-dose</time_frame>
    <description>Riker Sedation-Agitation Scale is a arousal/sedation tool ranging from 1 (unarousable condition) to 7 (Dangerous agitation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Buccal Irritation</measure>
    <time_frame>1, 4 and 6 h post-dose</time_frame>
    <description>Buccal cavity will be examined for redness, inflammation and ulceration and the occurrence of buccal irritation will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From start of study drug administration up to Week 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product and no later than 3 days following the last dose of investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Vital Signs Reported as an Adverse Event</measure>
    <time_frame>From start of study drug administration up to 24 h post-dose</time_frame>
    <description>A change in the value of vital sign assessment can represent an AE if the change is clinically relevant or if, during treatment with the investigational product, a shift of a parameter is observed from a normal value to an abnormal value, or a further worsening of an already abnormal value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Clinical Laboratory Results Reported as an Adverse Event</measure>
    <time_frame>From start of study drug administration up to 24 h post-dose</time_frame>
    <description>Clinical laboratory (serum biochemistry and urinalysis) results out-of-range will be assessed and if they are clinically significant will be reported as AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as an Adverse Event</measure>
    <time_frame>From start of study drug administration up to 24 h post-dose</time_frame>
    <description>12-lead ECG will be performed. Any clinically significant change in ECG assessment will be reported as AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>30 min, 1, 4, 6 and 24 h post-dose</time_frame>
    <description>Oxygen saturation will be measured and recorded on room air. The investigator will record the oxygen saturation as well as the oxygen delivery system and amount of oxygen administered, if required</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>SHP615</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHP615</intervention_name>
    <description>SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).</description>
    <arm_group_label>SHP615</arm_group_label>
    <other_name>MHOS</other_name>
    <other_name>Midazolam hydrochloride oromucosal solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MHOS/SHP615</intervention_name>
    <description>MHOS/SHP615</description>
    <arm_group_label>SHP615</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who completed the SHP615-301 study and who tolerated and responded to
             treatment with MHOS/SHP615 in the hospital and/or emergency room, and are considered
             stable for discharge from the hospital.

          -  Subjects who are greater than (&gt;) 6 months and less than (&lt;) 18 years of age at the
             time of investigational product administration. If the subject's exact age is not
             known, the subject should be excluded.

          -  Parent, guardian, or legally authorized representative of the child who provides
             informed consent and assent (when applicable) to participate in the study after
             initial stabilization of the subject with SE in hospital or emergency room during the
             SHP615-301 study. The subject also provides informed consent prior to participation,
             where applicable.

          -  Parent, guardian, or legally authorized representative who have received appropriate
             training/education and are deemed qualified by the investigator and are willing to:

               1. Properly administer MHOS/SHP615.

               2. Record seizure information and dosing of MHOS/SHP615 in a subject diary
                  (including time of seizure onset, type of seizure, time necessary to administer
                  MHOS/SHP615, time between MHOS/SHP615 administration to seizure cessation, etc.)

               3. Follow the necessary instructions to secure the safety of the subject.

          -  Subjects who experience generalized tonic-clonic SE with seizures accompanied by loss
             of consciousness with any of the following characteristics persistent at the time of
             study drug administration:

               1. Currently presenting with seizure (convulsive) activity and 3 or more convulsions
                  within the preceding hour

               2. Currently presenting with seizure (convulsive) and 2 or more convulsions in
                  succession without recovery of consciousness.

               3. Currently presenting with a single seizure (convulsive) persisting greater than
                  or equal to (&gt;=) 5 minutes.

        Exclusion Criteria:

          -  Female subjects who are pregnant, suspected to be pregnant, or nursing.

          -  Subjects with major trauma, not necessarily restricted to the head, as the cause of
             the seizure.

          -  Subjects with known or suspected recurrent seizures due to illegal drug or alcohol
             withdrawal.

          -  Subjects with seizures due to illegal drug or acute alcoholic intoxication.

          -  Subjects with seizures of psychogenic origin.

          -  Subjects with seizures due to severe encephalitis or meningitis, as determined by the
             PI

          -  Subjects with known history of hypersensitivities, nonresponsiveness or
             contraindications to benzodiazepines (that is (ie), clinically significant respiratory
             depression, severe acute hepatic failure, myasthenia gravis, syndrome of sleep apnea,
             glaucoma with closed angle, or use of concomitant drugs determined by the investigator
             to have a contraindication to the use of benzodiazepines.)

          -  Subjects with a known history of benzodiazepine abuse.

          -  Subjects who have not responded to previous administrations of midazolam systemic
             therapies, including MIDAFRESA and/or DORMICUM.

          -  Subjects who need emergent surgical intervention and general anesthesia/intubation.

          -  Subjects who have been receiving human immunodeficiency virus (HIV) protease
             inhibitors or HIV reverse transcriptase inhibitors.

          -  Subjects with severe cerebral anoxia (except cerebral palsy), in the judgment of the
             healthcare provider.

          -  Have used an investigational product or been enrolled in a clinical study (including
             vaccine studies) that, in the investigator's opinion, may impact this Shire-sponsored
             study.

          -  Subject has prior placement of a vagus nerve stimulator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>216 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu</city>
        <state>Fujimi</state>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takuaki Oba</last_name>
      <email>t-oba@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Yusuke Goto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chika Holloway</last_name>
      <email>holloway@huhp.hokudai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hideaki Shiraishi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Minami-Okayama Medical Center</name>
      <address>
        <city>Okayama</city>
        <state>Okayama Prefecture</state>
        <zip>701-0304</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miyuzu Taniguchi</last_name>
      <email>taniguchi.miyuzu@nagasaki-mc.com</email>
    </contact>
    <investigator>
      <last_name>Harumi Yoshinaga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Yachiyo Medical Center</name>
      <address>
        <city>Yachiyo</city>
        <state>Owada Shinden</state>
        <zip>276-8524</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juri Obata</last_name>
      <email>juri-obata@irom.co.jp</email>
    </contact>
    <investigator>
      <last_name>Junichi Takanashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Institute of Epilepsy and Neurological Disorders</name>
      <address>
        <city>Shizuoka</city>
        <state>Shizuoka Prefecture</state>
        <zip>420-8688</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshiaki Yamamoto</last_name>
      <email>yamamoty@shizuokamind.org</email>
    </contact>
    <investigator>
      <last_name>Asako Horino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital(NW)</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shino Ohmura</last_name>
      <email>s-ohmura@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Ryutaro Kira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gifu Prefectural General Medical Center</name>
      <address>
        <city>Gifu</city>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mayumi Sasada</last_name>
      <email>sasada.mayumi@neues.co.jp</email>
    </contact>
    <investigator>
      <last_name>Atsushi Imamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Hokkaido Medical Center</name>
      <address>
        <city>Hokkaid≈ç</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshiyuki Hori</last_name>
      <email>horiyel@hok-mc.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Masayoshi Nagao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumamoto Saishunso National Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akiko Nishioka</last_name>
      <email>anishioka@saisyunsou1.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Chizuru Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Nagasaki Medical Center</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miyuzu Taniguchi</last_name>
      <email>taniguchi.miyuzu@nagasaki-mc.com</email>
    </contact>
    <investigator>
      <last_name>Shigeki Tanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Nishi Niigata Chuo National Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emi Takahashi</last_name>
      <email>chiken-kango01@masa.go.jp</email>
    </contact>
    <investigator>
      <last_name>Jun Tohyama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Children's Health and Medical Center(NW)</name>
      <address>
        <city>Obu</city>
        <zip>474-8710</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yukiko Sone</last_name>
      <email>sone.yukiko@e-smo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Kazuya Itomi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-0914</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroto Okuda</last_name>
      <email>okuda-h@cc.okayama-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Katsuhiro Kobayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nakano Children's Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>535-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atsuko Nakata</last_name>
      <email>at-nakata@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Kiyotaka Murakami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital(NW)</name>
      <address>
        <city>Osaka</city>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michiko Yamazaki</last_name>
      <email>michiko@mch.pref.osaka.jp</email>
    </contact>
    <investigator>
      <last_name>Yasuhiro Suzuki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jichi Children's Medical Center Tochigi</name>
      <address>
        <city>Saitama-shi</city>
        <zip>330-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kuniko Suzuki</last_name>
      <email>ksuzuki@jichi.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hitoshi Osaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama Children's Medical Center(NW)</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mika Arai</last_name>
      <email>mk-arai@epsogo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Shinichiro Hamano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nozomi Okuda</last_name>
      <email>okuda.nozomi@neues.co.jp</email>
    </contact>
    <investigator>
      <last_name>Haruo Shintaku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keiko Sato</last_name>
      <email>keiko.yagi@miraca.com</email>
    </contact>
    <investigator>
      <last_name>Hirokazu Oguni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center Hospital, NCNP</name>
      <address>
        <city>Tokyo</city>
        <zip>187-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hiroko Harada</last_name>
      <email>chiken27@ncnp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Eiji Nakagawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshihiro Maegaki</last_name>
    </contact>
    <investigator>
      <last_name>Yoshihiro Maegaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Yamadaoka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miyuki Takamura</last_name>
      <email>miyuki-takamura@ocrcn.or.jp</email>
    </contact>
    <investigator>
      <last_name>Kuriko Shimono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Children's Medical Center(NW)</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emiko Miura</last_name>
      <email>emiura@kcmc.jp</email>
    </contact>
    <investigator>
      <last_name>Tomohide Goto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

